bims-dinmec Biomed News
on DNA methylation in cancer
Issue of 2026–11–01
three papers selected by
Lorena Ancona, Humanitas Research



  1. Genes (Basel). 2026 Sep 22. pii: 1160. [Epub ahead of print]17(10):
       BACKGROUND/OBJECTIVES: Uterine serous carcinoma (USC) is a deadly form of Type II endometrial cancer of rising incidence in the USA. It is currently thought to originate in the uterus, but emerging evidence suggests USC etiology is more complex and may involve the fallopian tube. DNA methylation is an inheritable suppressive epigenetic marker that can differentiate cellular origins, so we opted to perform a study comparing DNA methylation of USC to the fallopian tube and uterus.
    METHODS: DNA methylation profiles were compared between USC, fallopian tube epithelium (FTE), normal uterus, and a cancer known to primarily originate from FTE: high-grade serous ovarian cancer (HGSC). Hierarchical clustering of DNA methylation was performed. Variably DNA-methylated genes were defined for tumors and the FTE relative to normal uterus.
    RESULTS: Hierarchical clustering of USC separated USC from normal uterus but showed similarity with some FTE profiles, such as HGSC. Differentially methylated genes in USC correspond to both known and novel genes related to USC biology. Known biomarkers included hypomethylation of PAX8 in both HGSC and USC, which is often used in histopathology. Another known histopathological marker is WT1, which is more often expressed in HGSC than USC. By DNA methylation, hypomethylation was observed with WT1 in HGSC, whereas in USC WT1 hypermethylation was observed. Other novel markers of interest are discussed within.
    CONCLUSIONS: There is substantial overlap in DNA methylation biomarkers between the fallopian tube epithelium and USC tumors, just like the known FTE-originating carcinoma: HGSC. These results are supportive of the possibility of certain USCs arising first from the FTE (thereby retaining inheritable DNA methylation markers from the FTE) and then metastasizing to the uterus.
    Keywords:  DNA methylation; cell-of-origin; epigenetics; high-grade serous ovarian cancer; uterine serous carcinoma
    DOI:  https://doi.org/10.3390/genes17101160
  2. Proc Natl Acad Sci U S A. 2026 Nov 03. 123(44): e2615533123
      The human genome consists of nearly 50% repetitive DNA, referred to for decades as "junk DNA." These repetitive sequences, usually under the strict control of epigenetic silencing, can become aberrantly expressed in cancer. Some of these expressed sequences, e.g., transposable elements (TEs), can induce innate immune responses when derepressed following treatment with epigenetic therapies. As a result, epigenetic therapy has been suggested to augment cancer therapies. TEs are traditionally ignored in most RNA-seq studies and their expression is often excluded from publicly available data sources. Thus, the vast amount of publicly available RNA-seq data is an untapped resource for exploring the role of TE expression in cancer and cancer treatment. Here, we present a uniform reanalysis of over 7,000 RNA-seq samples, encompassing more than 2,000 differential expression experiments across 220 cancer cell lines and 700 drug treatments. We observed that TE expression is more prone to batch effects than gene expression alone, necessitating the use of meta-analysis techniques to probe the dataset for global trends. We confirm that DNMTi and HDACis are powerful inducers of TE expression. We also show that nonepigenetic compounds such as cyclin-dependent kinase and topoisomerase inhibitors can also induce robust up-regulation of TE-derived repetitive DNA elements and confirm that this induction is consistent with transcriptional signatures of viral mimicry response. We made all data available through a publicly available database called the Transposable Element Differential Expression Database, or TEDEdb, and created an interactive web application for its exploration located at https://dataexplorer.coriell.org/TEDEdb/.
    Keywords:  RNA-seq; cancer; database; epigenetics; transposable elements
    DOI:  https://doi.org/10.1073/pnas.2615533123
  3. Eur J Cancer. 2026 Oct 28. pii: S0959-8049(26)00858-0. [Epub ahead of print]249 117076
    Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium
       BACKGROUND: Only a subset of patients with esophageal adenocarcinoma (EAC) achieve complete or partial histopathological response to immunotherapy, highlighting the need for better understanding of the tumor microenvironment (TME). Despite efforts to characterize the EAC TME at the molecular level, its epigenetic landscape remains understudied.
    METHODS: We combined bulk DNA methylation data from a large Norwegian multicenter EAC cohort (n = 232) with immune gene annotations to identify immune-related CpG sites differentially methylated between tumor and normal tissue. Hierarchical consensus clustering of EAC samples based on these sites was performed, and the identified subtypes were characterized according to their immune cell type composition, association with clinical features and potential prognostic relevance.
    RESULTS: We identified four immune subtypes (IS1-IS4) with distinct DNA methylation patterns and tumor-infiltrating immune cell composition. The highest DNA methylation levels at immune-related CpG sites were found in IS3, which showed the lowest relative fractions of CD8+ T cells and the highest fractions of regulatory T cells (Tregs), consistent with an immunosuppressed phenotype. Conversely, IS1, with the lowest DNA methylation levels at immune-related CpG sites, displayed the highest relative fractions of CD8+ T cells and the lowest fractions of Tregs, aligning with an "inflamed" immune profile. These findings were validated in an independent multicenter cohort (n = 285). No significant differences in 5-year overall survival were observed across immune subtypes, possibly reflecting the influence of variable response to neoadjuvant treatment.
    CONCLUSION: The identified immune subtypes offer new insights into the epigenetic landscape of the EAC TME and reveal differences in its cellular composition.
    Keywords:  Epigenetic profiling; Immune landscape; Immunotherapy; Molecular stratification; Tumor content; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.ejca.2026.117076